R-CHMP regimen: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
{{SK}} Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Marqibo-Prednisone regimen | {{SK}} Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Marqibo-Prednisone regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[cyclophosphamide]] , [[doxorubicin|doxorubicin (hydroxydaunorubicin)]], [[Vincristine|vincristine (Marqibo)]], and [[prednisone]] used to treat aggressive [[non-Hodgkin's lymphoma]].<ref name="pmid23802738">{{cite journal| author=Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A et al.| title=Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. | journal=Br J Haematol | year= 2013 | volume= 162 | issue= 5 | pages= 631-8 | pmid=23802738 | doi=10.1111/bjh.12446 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23802738 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[cyclophosphamide]] , [[doxorubicin|doxorubicin (hydroxydaunorubicin)]], [[Vincristine|vincristine (Marqibo)]], and [[prednisone]] used to treat aggressive [[non-Hodgkin's lymphoma]].<ref name="pmid23802738">{{cite journal| author=Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A et al.| title=Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. | journal=Br J Haematol | year= 2013 | volume= 162 | issue= 5 | pages= 631-8 | pmid=23802738 | doi=10.1111/bjh.12446 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23802738 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 23: | Line 21: | ||
==Indications== | ==Indications== | ||
* [[Non-Hodgkin's lymphoma]]<ref name="pmid23802738">{{cite journal| author=Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A et al.| title=Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. | journal=Br J Haematol | year= 2013 | volume= 162 | issue= 5 | pages= 631-8 | pmid=23802738 | doi=10.1111/bjh.12446 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23802738 }} </ref> | * [[Non-Hodgkin's lymphoma]]<ref name="pmid23802738">{{cite journal| author=Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A et al.| title=Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. | journal=Br J Haematol | year= 2013 | volume= 162 | issue= 5 | pages= 631-8 | pmid=23802738 | doi=10.1111/bjh.12446 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23802738 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 16:38, 31 March 2015
|
WikiDoc Resources for R-CHMP regimen |
|
Articles |
|---|
|
Most recent articles on R-CHMP regimen Most cited articles on R-CHMP regimen |
|
Media |
|
Powerpoint slides on R-CHMP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-CHMP regimen at Clinical Trials.gov Trial results on R-CHMP regimen Clinical Trials on R-CHMP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-CHMP regimen NICE Guidance on R-CHMP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-CHMP regimen Discussion groups on R-CHMP regimen Patient Handouts on R-CHMP regimen Directions to Hospitals Treating R-CHMP regimen Risk calculators and risk factors for R-CHMP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-CHMP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Marqibo-Prednisone regimen
Overview
R-CHMP regimen refers to a regimen consisting of rituximab, cyclophosphamide , doxorubicin (hydroxydaunorubicin), vincristine (Marqibo), and prednisone used to treat aggressive non-Hodgkin's lymphoma.[1]
Regimen
RRituximab (Rituxan)
CCyclophosphamide (Cytoxan)
HDoxorubicin (Hydroxydaunorubicin)
MVincristine liposomal (Marqibo)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A; et al. (2013). "Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas". Br J Haematol. 162 (5): 631–8. doi:10.1111/bjh.12446. PMID 23802738.